An observational study in Hyperandrogenism, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to female participants aged 16 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Hyperandrogenism is a common reason for consultation, the causes of which can range from common conditions (PCOS) to rarer conditions with major genetic implications (NC21OHD). It is characterized by elevated levels of circulating androgens, mainly testosterone. This excess of androgens usually manifests clinically as increased male-pattern hair growth and, less specifically, acne and alopecia. Its prevalence is estimated at between 6 and 12% in women of reproductive age, and its incidence is increasing.
It is also responsible for infertility. As a reminder, infertility is a major public health issue and affects more and more couples around the world.
The investigators therefore wish to develop innovative tools to improve the diagnosis and management of hyperandrogenism
Hyperandrogenism is a common reason for consultation, the causes of which can range from common conditions (PCOS) to rarer conditions with major genetic implications (NC21OHD). It is characterized by elevated levels of circulating androgens, mainly testosterone. This excess of androgens usually manifests clinically as increased male-pattern hair growth and, less specifically, acne and alopecia. Its prevalence is estimated at between 6 and 12% in women of reproductive age, and its incidence is increasing.
It is also responsible for infertility. As a reminder, infertility is a major public health issue and affects more and more couples around the world.
The investigators therefore wish to develop innovative tools to improve the diagnosis and management of hyperandrogenism
81 studies on the registry are indexed under Hyperandrogenism; 22 are open to participants now.
This study's planned enrollment of 800 is above the median of 135 across 26 observational studies indexed under Hyperandrogenism.
Browse Hyperandrogenism studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The first stage of the study will involve participating centers selecting patients' medical records after verifying their eligibility. It should be noted that the control group will consist of a population for whom tests were carried out for symptoms that were ultimately ruled out with normal results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: data collection
collection of data from medical records over a period of 5 years
Use of machine learning models combined with metabolomics to distinguish between different causes of hyperandrogenism
Time frame: 5 years
Use of metabolomics to improve the management of patients with hyperandrogenism
Time frame: 5 years
Use of metabolomics to predict CYP21A2 genotyping results
Time frame: 5 years
Study of the impact of anti-androgenic hormone therapy on the predictive capabilities of the model
Time frame: 5 years
No study locations are listed for this record.
Plan to share: Yes — The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.
Supporting information: Study protocol, Informed consent form
Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Dec 2040, 179 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →